Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group-Reference-Cited by-同舟云学术

Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group

Published:2018-02 Issue:1 Volume:18 Page:88-94
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Saloustros Emmanouil^ORCID,Nikolaou Michail,Kalbakis Konstantinos,Polyzos Aris,Christofillakis Charalampos,Kentepozidis Nikolaos^ORCID,Pistamaltzian Nikolaos,Kourousis Charalampos,Vamvakas Lampros,Georgoulias Vasilios,Mavroudis Dimitris

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis;Forouzanfar;Lancet,2011

2. Gene-expression signatures in breast cancer;Sotiriou;N Engl J Med,2009

3. Triple-negative breast cancer;Foulkes;N Engl J Med,2010

4. Molecular portraits of human breast tumours;Perou;Nature,2000

5. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma;Nielsen;Clin Cancer Res,2004

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Thienopyrimidine-Hydrazinyl Compounds Induce DRP1-Mediated Non-Apoptotic Cell Death in Triple-Negative Breast Cancer Cells;Cancers;2024-07-23

2. Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison;Clinical Breast Cancer;2023-04

3. Alternative Polyadenylation alters UBASH3B-ZNF652 competition to involve in Triple-Negative Breast Cancer;2022-12-30

4. A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer;Nature Communications;2022-07-12

5. Recent progress in antibody-based therapeutics for triple-negative breast cancer;Expert Opinion on Drug Delivery;2022-07-03